Combined cytoplasmic and membranous EGFR and p53 overexpression is a poor prognostic marker in early stage oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 41, Issue 7, 2012, Pages 559-567

  Monteiro, Luís Silva ^a   Diniz Freitas, Márcio ^b   Garcia Caballero, Tomás ^c   Warnakulasuriya, Saman ^d   Forteza, Jerónimo ^c   Fraga, Máximo ^c  

^a UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d King's and St Thomas' School of Medicine and Dentistry   (United Kingdom)

Author keywords

EGFR; Oral squamous cell carcinoma; P16; P27; P53; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE; CELL MEMBRANE; COHORT ANALYSIS; CYTOPLASM; FEMALE; GENE OVEREXPRESSION; GROWTH REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864395173     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2012.01142.x     Document Type: Article

References (61)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer, 2010.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-16.
3. Schmitz S, Machiels JP. Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications. Expert Rev Anticancer Ther 2010; 10: 1471-84.
4. Hahn WC, Weinberg RA. Rules for making human tumors cells. N Engl J Med 2002; 347: 1593-603.
5. O-charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA. C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 2002; 38: 73-80.
6. Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 2003; 3: 367-80.
7. Diniz-Freitas M, García-Caballero T, Antúnez-López J, Gándara-Rey JM, García-García A. Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis 2007; 13: 285-90.
8. Störkel S, Reichert T, Reiffen KA, Wagner W. EGFR and PCNA expression in oral squamous cell carcinomas--a valuable tool in estimating the patient's prognosis. Eur J Cancer B Oral Oncol 1993; 29: 273-7.
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
10. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-57.
11. Abbas NF, Labib El-Sharkawy S, Abbas EA, El-Shaer AM. Immunohistochemical study of p53 and angiogenesis in benign and preneoplastic oral lesions and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 385-90.
12. Rodolico V, Aragona F, Cabibi D, et al. Overexpression of cyclin D1 and interaction between p27Kip1 and tumour thickness predict lymph node metastases occurrence in lower lip squamous cell carcinoma. Oral Oncol 2005; 41: 268-75.
13. Rodolico V, Barresi E, Di Lorenzo R, et al. Lymph node metastasis in lower lip squamous cell carcinoma in relation to tumour size, histologic variables and p27Kip1 protein expression. Oral Oncol 2004; 40: 92-8.
14. Sartor M, Steingrimsdottir H, Elamin F, et al. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer 1999; 80: 79-86.
15. Sailasree R, Abhilash A, Sathyan KM, Nalinakumari KR, Thomas S, Kannan S. Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 414-20.
16. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999; 5: 2810-9.
17. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. American Joint Committee on Cancer: AJCC - Cancer Staging Manual, 7th edn. New York: Springer, 2010;1-40.
18. Barnes L, Everson JW, Reichart P, Sidransky D. World health organization classification of tumours: pathology and genetics of head and neck tumours. Lyon, France: IARC Press, 2005.
19. Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Forteza J, Fraga M. EGFR and Ki-67 expression in oral squamous cell carcinoma using tissue microarray technology. J Oral Pathol Med 2010; 39: 571-8.
20. Jourdan F, Sebbagh N, Comperat E, et al. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 2003; 443: 115-21.
21. Tanière P, Martel-Planche G, Saurin JC, et al. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. Br J Cancer 2001; 85: 721-6.
22. Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, et al. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin Cancer Res 2004; 10: 8486-92.
23. Ch'ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 2008; 39: 344-9.
24. Laimer K, Spizzo G, Gasti G, et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analisis. Oral Oncol 2007; 43: 193-8.
25. Kusukawa J, Harada H, Shima I, Sasaguri Y, Kaneyama T, Morimatsu M. The significance of epidermal growth factor receptor and matrix metalloproteinase-3 in squamous cell carcinoma of oral cavity. Eur J Cancer Oral Oncol 1996; 32: 217-21.
26. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area. Br J Cancer 2003; 89: 681-6.
27. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25: 2164-70.
28. Ulanovski D, Stern Y, Roizman P, Shpitzer T, Popovtzer A, Feinmesser R. Expression of EGFR and Cerb-B2 as prognostic factors in cancer of the tongue. Oral Oncol 2004; 40: 532-7.
29. Monteiro LS, Bento MJ, Palmeira C, Lopes C. Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours. J Oral Pathol Med 2009; 38: 508-13.
30. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.
31. Christensen ME, Engbaeck F, Therkildsen MH, Bretlau P, Nexo E. A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: evaluation, interpretations and limitations. Br J Cancer 1995; 72: 1487-93.
32. Bànkfalvi A, Piffkò J. Prognostic and predictive factors in oral cancer: the role of invasive tumour front. J Oral Pathol Med 2000; 29: 291-8.
33. Agra IM, Carvalho AL, Pinto CA, et al. Biological markers and prognosis in recurrent oral cancer after salvage surgery. Arch Otolaryngol Head Neck Surg 2008; 134: 743-9.
34. Schartinger VL, Kacani L, Ardle J, et al. Pharmacodiagnostic value of the HER family in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 2004; 66: 21-6.
35. Smid EJ, Stoter TR, Bloemena E, et al. The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65: 1323-9.
36. Fischer C, Zlobec I, Stöckli E, et al. Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas Human Pathol 2008; 39: 1527-34.
37. Del Sordo R, Angiero F, Bellezza G, et al. HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance. J Oral Pathol Med 2010; 39: 79-86.
38. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52: 893-901.
39. Muller S, Su L, Tighiouart M, et al. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation. Cancer 2008; 113: 97-107.
40. Maiorano E, Favia G, Maisonneuve P, Viale G. Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa. J Pathol 1998; 185: 167-74.
41. Karsai S, Abel U, Roesch-Ely M, et al. Comparison of p16(INK4a) expression with p53 alterations in head and neck cancer by tissue microarray analysis. J Pathol 2007; 211: 314-22.
42. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3.
43. Calmon MF, Colombo J, Carvalho F, et al. Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. Cancer Genet Cytogenet 2007; 173: 31-7.
44. Uzawa N, Sonoda I, Myo K, Takahashi K, Miyamoto R, Amagasa T. Fluorescence in situ hybridization for detecting genomic alterations of cyclin D1 and p16 in oral squamous cell carcinomas. Cancer 2007; 110: 2230-9.
45. Shah NG, Trivedi TI, Tankshali RA, et al. Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck 2009; 31: 1544-56.
46. González-Moles MA, Gil-Montoya JA, Ruiz-Avila I, Esteban F, Delgado-Rodriguez M, Bascones-Martinez A. Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer. Oncol Rep 2007; 18: 389-96.
47. Muirhead DM, Hoffman HT, Robinson RA. Correlation of clinicopathological features with immunohistochemical expression of cell cycle regulatory proteins p16 and retinoblastoma: distinct association with keratinisation and differentiation in oral cavity squamous cell carcinoma. J Clin Pathol 2006; 59: 711-5.
48. Smith EM, Wang D, Kim Y, et al. P16INK4a expression, human papillomavirus, and survival in head and neck cancer. Oral Oncol 2008; 44: 133-42.
49. Fillies T, Woltering M, Brandt B, et al. Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. Oncol Rep 2007; 17: 355-9.
50. Kudo Y, Takata T, Yasui W, et al. Reduced expression of cyclin-dependent kinase inhibitor p27 Kip1 is an indicator of malignant behaviour of oral squamous cell carcinomas. Cancer 1998; 83: 2447-55.
51. Kuo MY, Hsu HY, Kok SH, et al. Prognostic role of p27 (Kip1) expression in oral squamous cell carcinoma in Taiwan. Oral Oncol 2002; 38: 172-8.
52. Fujieda S, Inuzuka M, Tanaka N, et al. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 1999; 84: 315-20.
53. Shintani S, Mihara M, Nakahara Y, et al. Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol 2002; 38: 235-43.
54. Nagler RM, Kerner H, Laufer D, Ben-Eliezer S, Minkov I, Ben-Itzhak O. Squamous cell carcinoma of the tongue: the prevalence and prognostic roles of p53, Bcl-2, c-erbB-2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study. Cancer Lett 2002; 186: 137-50.
55. Xie X, Clausen OPF, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, bax, bcl-2 and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999; 86: 913-20.
56. Rittà M, De Andrea M, Mondini M, et al. Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. Head Neck 2009; 31: 318-27.
57. Oliveira LR, Ribeiro-Silva A, Costa JP, Simões AL, Matteo MA, Zucoloto S. Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 685-95.
58. Oliveira LR, Ribeiro-Silva A, Zucoloto S. Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma. J Oral Pathol Med 2007; 36: 191-7.
59. Baltaziak M, Duraj E, Koda M, et al. Expression of Bcl-xL, Bax, and p53 in primary tumors and lymph node metastases in oral squamous cell carcinoma. Ann N Y Acad Sci 2006; 1090: 18-25.
60. Warnakulasuriya S, Jia C, Johnson N, Houghton J. p53 and P-Glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy. J Pathol 2000; 191: 33-8.
61. Wilson GD, Richman PI, Dische S, et al. The p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br J Cancer 1995; 71: 1248-52.